Question: Protein kinase inhibitors have become a major focus for the development of molecularly targeted cancer therapies. Based on what you know from the development of Gleevec, what are at least two generalizable principles that apply to the development of all tyrosine kinase inhibitors? What is a potential pitfall of targeting a protein kinase for cancer treatment? (This answer should include three separate concepts - 2 principles, 1 limitation)